Blood tests for Alzheimer's disease: The impact of disease prevalence on test performance
Open Access
- 6 March 2024
- journal article
- letter
- Published by Wiley in Alzheimer's & Dementia
- Vol. 20 (5) , 3661-3663
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- Personal value of Alzheimer's disease biomarker testing and result disclosure from the patient and care partner perspectiveAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2024
- P.006 Alzheimer’s disease CSF biomarker testing and its impacts on clinical management: findings from the IMPACT-AD BC studyCanadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques, 2023
- Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer’s diseaseBrain, 2022
- The Alzheimer's Association appropriate use recommendations for blood biomarkers in Alzheimer's diseaseAlzheimer's & Dementia, 2022
- Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical SpectrumJAMA Neurology, 2022
- Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer DiseaseJAMA Neurology, 2021
- Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or DementiaJAMA, 2019
- Prevalence of abnormal Alzheimer’s disease biomarkers in patients with subjective cognitive decline: cross-sectional comparison of three European memory clinic samplesAlzheimer's Research & Therapy, 2019
- Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's diseaseAlzheimer's & Dementia, 2018